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Abstract
Background:  Jacobsen syndrome (JBS) is a rare chromosomal disorder leading to multiple
physical and mental impairment. This syndrome is caused by a partial deletion of chromosome 11,
especially subband 11q24.1 has been proven to be involved. Clinical cases may easily escape
diagnosis, however pancytopenia or thrombocytopenia may be indicative for JBS.
Results: We report a 7.5 years old boy presenting with speech development delay, hearing
impairment and abnormal platelet function. High resolution SNP oligonucleotide microarray
analysis revealed a terminal deletion of 11.4 Mb in size, in the area 11q24.1-11qter. This specific
deletion encompasses around 170 genes. Other molecular techniques such as fluorescence in situ
hybridization and multiplex ligation-dependent probe amplification were used to confirm the array-
result.
Discussion: Our results suggest that the identification and detailed analysis of similar patients with
abnormal platelet function and otherwise mild clinical features will contribute to identification of
more patients with 11q deletion and JBS.
Background
Jacobsen syndrome (JBS) is a rare inherited disorder with
variable phenotypic expression and partial deletion of
chromosome 11q. To date more than 200 cases were
reported, with an estimated prevalence of 1/100,000
births [1]. Clinical manifestations of JBS typically include
developmental and mental retardation, facial dysmor-
phism, congenital heart defects, and thrombocytopenia
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[2-5]. In more detail typical JBS features include short stat-
ure, mental retardation, congenital heart defects, throm-
bocytopenia and characteristic facial dysmorphism
consisting of skull deformities, ocular hypertelorism, pto-
sis, downward slanting palpebral fissures, epicanthal
folds, flat nasal bridge, short nose with flat philtrum and
thin upper lip, v-shaped mouth and small and low set
ears. The neck is short, the hands show cutaneous syndac-
tyly, the fingers are thin with flat finger pads and the feet
are stubby, flat with clinodactylous toes. Malformations
of kidneys are present in 13% of cases, gastrointestinal
tract problems in 18%, abnormal genitalia in 36%, central
nervous system and skeletal dysplasias in 14%. Abnormal
platelet function, thrombocytopenia or pancytopenia is
affecting at least 88% of cases and is usually present from
birth [6,7]. About 20% of the children die during the first
two years of life most commonly related to complications
from congenital heart disease and less commonly from
bleeding. Mental retardation is observed in 97% of cases
while normal or borderline cognitive function is observed
in less than 3% of cases. Behavioural problems such as
attention deficit/hyperactivity disorders and psychiatric
disorders have been rarely reported. Hearing impairment
is not a common symptom but should be excluded in all
patients with JBS. Immunological and hormonal prob-
lems may also be present. There is a wide range of severity
of the clinical phenotype of JBS patients.
Dependent on the size of the 11q deletion, which usually
lies between 7 and 20 Mb [8,9], the clinical features may
vary also. Previous cytogenetic studies in JBS patients
characterized the crucial band for the 11q monosomy syn-
drome as being 11q24.1 [10]. A genotype-phenotype cor-
relation of 14 JBS patients found that 9 patients with a
deletion of at least 12.1 Mb had severe global cognitive
impairment, whereas the other 5 patients with deletion
equal to or smaller than 11.8 Mb demonstrated mild cog-
nitive impairment [11]. Partial expression of the JBS phe-
notype was observed in cases of very small terminal
deletions or interstitial deletions within the JBS region
[4,12,13].
Overall, many of the JBS symptoms are relatively unspe-
cific. Especially in such cases with mild clinical symptoms,
pancytopenia or thrombocytopenia may be suggestive for
a JBS diagnosis [12,13].
Here we report a JBS case with abnormal platelet function,
normal physical and mental development, mild facial
dysmorphism, not age-appropriate language skills, and
hearing impairment with partial deletion of distal chro-
mosome 11q.
Case presentation
The patient, a 7 years and 6 months old boy, was the sec-
ond child of unrelated healthy parents. He was born by
cesarean section after a full term pregnancy. His birth
weight was 3,250 kg (50 percentile), length 50 cm (50 per-
centile) and head circumference (HC) 35.5 cm (50 per-
centile). His perinatal period was without problems. The
motor development was normal as he sat independently
at the age of 7 months and walked unassisted at the age of
11 months. His language development was delayed; first
words were spoken later than aged 2 years and 6 months,
and at 5 years he was referred to logotherapy. His parents
described him as a healthy, sociable and smart boy with
low linguistic skills. When the patient attended 1st grade
in the mainstream school he was referred by his school-
teacher for full developmental assessment because of
learning difficulties and speech developmental delay.
On physical examination he was quite a sociable child,
with mild dysmorphic facial features such as ocular hyper-
telorism, downward slanting palpebral fissures, epi-
canthal folds, flat nasal bridge, short nose with flat
philtrum, and thin upper lip. Additionally, his neck was
short and the feet were stubby and flat. His weight was 27
kg (50th percentile), height 122 cm (25th percentile) and
his HC 52 cm (25th percentile). On developmental exam-
ination: his nonverbal skills were equivalent to a 5 years 9
months level with good language understanding, being
able to spell, read and write small words, but his oral
speech development was very poor. His expressive lan-
guage was limited to small words and phrases with many
phonological difficulties. According to Griffiths Mental
Development Scales and Bayley Scales of Infant Develop-
ment (2nd edition) his General Developmental Quotient
(GDQ) was 78 with performance DQ of 86 and language
DQ of 61. His behavior was normal for developmental
age.
On neurological examination he was slightly hypotonic
but without asymmetry. Heart auscultation revealed a
mild systolic murmur. Audiological examination showed
a mild bilateral selective high frequency hearing loss
(4000-8000 Hz). Heart ultrasound (triplex) showed a sin-
gle papillary muscle resulting in mild mitral valve regurgi-
tation but without hemodynamic changes. The
echocardiogram was normal. Full ophthalmologic exami-
nation was normal. Hematological tests revealed anemia
with Hb of 9.3 g/100 ml, Ht of 30%, MCV of 57.9, MCH
of 18, and MCHC of 31 g/100 ml, with normal blood cell
and platelet counts 269,000/μl (140,000/μl-300,000/μl).
Bleeding time was very elongated >17 min (2-4 min) and
platelet aggregation test (PSA) was abnormal 196 sec
(<142 sec).
Results of further biochemical tests were the following:
urea: 34 mg/dl, blood sugar: 86 mg/dl, creatinine: 0.35
mg/dl, calcium: 9.4 mg/dl, Mg: 2.5 mg/dl, K: 4.8 mEq/l,
Na: 140 mEq/l, Cl:106 mEq/l, SGOT: 40 U/l, SGPT: 30 U/
l, GT: 8 U/l, cholesterol: 132 mg/dl, HD: 61 mg/dl, LDL:Molecular Cytogenetics 2009, 2:26 http://www.molecularcytogenetics.org/content/2/1/26
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59 mg/dl, CPK: 65 u/l, and ammonia: 0.69 μg/dl. Thyroid
function and kidney-liver-spleen ultrasound were also
normal.
Results
Chromosome analysis of the patient was performed using
GTG-banding techniques on stimulated blood lym-
phocytes. Cytogenetics revealed a deletion of the long arm
of one chromosome 11 in the band q24.1 (Fig. 1B). Fluo-
rescence in situ hybridization (FISH) using a commercially
available subtelomeric probe (Abbott/Vysis) for 11qter
confirmed the suggested deletion. The parental karyo-
types were normal, suggesting a de novo appearance of
the deletion.
The multiplex ligation-dependent probe amplification
(MLPA) technique was performed using the SALSA P036B
probe set (MRC-Holland) containing probes for all subte-
lomeric regions, which confirmed the deletion (data not
shown). Finally, single nucleotide polymorphism (SNP)
oligonucleotide microarray analysis (SOMA) was per-
formed on DNA of the patient. Thus, the size of the dele-
tion was determined as 11.4 Mb, in the region 11q24.1-
11qter. The deleted segment extended from 123,073,531
to 134,449,982 bps on chromosome 11 (Fig. 1A).
Discussion
We report a 7.5 years old boy with an 11.4 Mb terminal
deletion of 11q24.1-qter characterized by high-resolution
SNP oligonucleotide microarray. The detected size of the
deletion and the observed comparatively mild symptoms
fit well to the previously defined cut off size of 11.8 Mb for
mild cases [12]
Tyson et al. [14] suggest that a critical region for the
conotruncal heart defect associated with JBS may lie
within a region spanning between 129.03 and 130.6 Mb,
which contains ADAMTTS8, a gene involved in angiogen-
esis [15]. Polymorphisms in the SNX19 gene have been
proposed to be associated with coronary disease [16] and
the JAM3 gene has previously been proposed as a candi-
date gene for the JBS cardiac phenotype. The megakaryo-
cytic defects in 14 Jacobsen syndrome patients were
mapped to a minimal region of overlap in 11q that
includes the FLI1 gene, thus suggesting that dysmegakary-
opoiesis in these patients may be caused by hemizygous
loss of FLI1 [17]. The heart defect present in our case was
a mitral valve regurgitation, which is not a heart defect
classically described in JBS.
Thrombocytopenia in JBS is usually chronic. Abnormal
platelets are detected with giant granules and the bone
marrow shows many micromegakaryocytes. Moreover,
electron microscopy reveals granule fusion within blood
platelets [6]. In our patient hemizygosity of the FLI1 gene
due to deletion of 11q24.3 was present together with
abnormal platelet function, which had passed notice up
to 7 years of age.
Like in our case, it is important to keep in mind that the
identification and further delineation with array-CGH
techniques of similar patients with mild features will con-
tribute to understand the genetic spectrum of the 11q phe-
notype.
Materials and methods
SNP Oligonucleotide Microarray Analysis (SOMA)
SOMA was performed using the Affymetrix Genome Wide
Human SNP Array 6.0, which includes over 906,600 sin-
gle nucleotide polymorphisms (SNPs) and more than
946,000 probes for the detection of copy number varia-
tion (CNV) in the human genome. Sample preparation,
hybridization and scanning were performed using Gene-
Chip® Instrument System hardware according to the man-
A. SNP Oligonucleotide Microarray Analysis (SOMA) identi- fies the deletion in the long arm of chromosome 11 Figure 1
A. SNP Oligonucleotide Microarray Analysis (SOMA) 
identifies the deletion in the long arm of chromo-
some 11. The deleted segment on chromosome 11 lies 
between marker SNP_A-2122040 at chr11: 123073531 and 
marker SNP_A-2246844 at chr11: 134449982, spanning an 
area of 11.37 Mb. B. Partial karyotype of chromosomes 
11 of the proband. Arrow shows the deleted chromosome 
segment.Molecular Cytogenetics 2009, 2:26 http://www.molecularcytogenetics.org/content/2/1/26
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ufacturer's specifications (Affymetrix, Santa Clara, CA).
Analysis was performed using the Affymetrix Genotyping
Console software (version 3.0.1). The samples met
Affymetrix recommended values for Contrast Quality
Control (QC) (SNP) and Median of the Absolute Values
of all Pairwise Differences (MAPD) QC (CNV). Data from
both SNP and copy number probes were used to identify
copy number aberrations compared to an internal refer-
ence set. The segment report was restricted to regions of
100 kb or greater with 10 or more consecutive probes that
differed significantly from the expected normalized dip-
loid values. The map positions of the deleted segment
refer to the Genome Assembly May 2004 (Build 35).
MLPA Analysis
MLPA with SALSA P036B and P070 probe mixes (MRC-
Holland) was performed in a GeneAmp PCR System 2700
(Applied Biosystems, Foster City, CA, USA) as recom-
mended by the manufacturer's protocol. PCR products
were electrophoresed in an ABI Prism 3100 Genetic Ana-
lyser and analysed with the GeneMapper 3.5 software
package (Applied Biosystems). Sequence deletion or
duplication was considered when a 35-50% variation of
the relative peak area of the amplification product of the
respective probe was obtained. If no concordant results
between the two probe mixes were obtained, the assay was
repeated.
Cytogenetics and FISH Analysis
Chromosome analysis was performed using GTG-band-
ing techniques on stimulated blood lymphocytes and
analyzed at 550-600 band resolution. Fluorescence in situ
hybridization (FISH) studies were performed using a set
of probes specific for the subtelomere of the 11q chromo-
some (Vysis/Abbott). Metaphase chromosomes were
obtained and fixed cell suspensions were dropped onto
clean microscope slides. A measure of 2.5 μl of the probe
was then placed on the glass slide with a coverslip. Cover-
slips were sealed with rubber cement and slides were
placed in a moist chamber and incubated overnight at
37°C. The slides were washed and counterstained with
DAPI, and cells were examined with a Zeiss Axioplan II,
Imager.M1 or Imager.Z1 fluorescence microscope
equipped with a triple-bandpass filter. Digital images
were captured and stored with Isis software V 3.4.0 (Meta-
systems, Altlussheim, Germany).
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